1 Mendelian randomization suggests a causal link between glycemic traits and thoracic

2 aortic structures and diseases.

- 3 Tselmen Daria¹, Kruthika Iyer^{1*}, Hasan Alkhairo^{1*}, Pik Fang Kho^{2,3*}, Ken Suzuki^{4,5,6,7},
- 4 Konstantinos Hatzikotoulas⁸, Lorraine Southam⁸, Henry J Taylor^{9,10,11}, Xianyong Yin¹², Ravi
- 5 Mandla^{13,14}, Alicia Huerta-Chagoya¹⁴, Nigel W Rayner¹⁵, Michael G. Levin^{16,17}, Scott M
- 6 Damrauer^{18,19}, Philip S Tsao^{3,20}, James R Priest²¹, James Pirruccello²², Justin B Echouffo
- 7 Tcheugui²³, Catherine Tcheandjieu^{1,24,3}
- 8

⁹ ¹Gladstone Institutes of Data Science and Biotechnology, Gladstone Institute, 1650 Owens

- 10 street, San Francisco, CA, 94158, USA, ²Departmen of medicine, Division of Cardiovascular
- 11 Medicine, Stanford University, 1650 Owens street, San Francisco, CA, 94158, USA, ³VA Palo
- 12 Alto Health Care System, CA, USA, ⁴Centre for Genetics and Genomics Versus Arthritis,
- 13 Division of Musculoskeletal and Dermatological Sciences, University of Manchester,
- 14 Manchester, UK, ⁵Centre for Musculoskeletal Research, University of Manchester, Manchester,
- 15 UK, ⁶Department of Diabetes and Metabolic Diseases, University of Tokyo, Tokyo, Japan,
- ⁷Department of Statistical Genetics, Graduate School of Medicine, Osaka University Graduate
- 17 School of Medicine, Tokyo, Japan, ⁸German Research Center for Environmental Health,
- 18 Institute of Translational Genomics, Helmholtz Zentrum München, Neuherberg, Germany,
- ⁹National Human Genome Research Institute, Center for Precision Health Research, National
- 20 Institutes of Health, Bethesda, MD, USA, ¹⁰Department of Public Health and Primary Care,
- 21 Center for Precision Health Research, University of Cambridge, Cambridge, MD, UK, ¹¹Heart
- 22 and Lung Research Institute, British Heart Foundation Cardiovascular Epidemiology Unit,
- 23 University of Cambridge, Cambridge, MD, UK, ¹²Department of Epidemiology, School of Public
- Health, Nanjing Medical University, 101 Longmian Avenue, Nanjing, Jiangsu, 211166, China,
- ¹³Department of Medicine, Diabetes Unit, Endocrine Division,, Massachusetts General Hospital,
- 26 Boston, MA, USA, ¹⁴Programs in Metabolism and Medical and Population Genetics, Broad
- 27 Institute of MIT and Harvard, Cambridge, MA, USA, ¹⁵German Research Center for
- 28 Environmental Health, Institute of Translational Genomics, Helmholtz Zentrum München,
- ¹⁶Department of Medicine, Division of Cardiovascular Medicine, University of Pennsylvania
- 30 Perelman School of Medicine, 3400 Civic Center Blvd., Philadelphia, PA, 19104, USA,
- 31 ¹⁷Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, 19104, USA, ¹⁸Department
- 32 of Medicine. Division of Cardiovascular Medicine. University of Pennsylvania Perelman School
- 33 of Medicine, Philadelphia, PA, USA, ¹⁹Corporal Michael Crescenz VA Medical Center,
- ²⁰Department of Medicine, Division of Cardiovascular Medicine, Stanford University, CA, USA,
- 35 ²¹Tenaya Therapeutics, South of San Francisco, CA, USA, ²²Division of Cardiology, University
- 36 of California San Francisco, San Francisco, CA, USA, ²³Department of Medicine, John Hopkins
- 37 University school of Medicine, Baltimore, MD, USA, ²⁴Department of epidemiology and
- 38 Biostatistics, University of California San Francisco, San Francisco, CA, USA
- 39
- 40 **Correspondence:** <u>Catherine.tcheandjieu@gladstone.ucsf.edu</u>
- 41 *Authors contributed equally
- 42

It is made available under a CC-BY-NC-ND 4.0 International license .

43 Abstract (max words count:350):

Importance: Type 2 diabetes mellitus (T2DM) and elevated glucose levels have been inversely
associated with aortic aneurysms. However, the causality of this relationship remains uncertain.
Additionally, there is a lack of studies investigating the association between glycemic traits and
imaging-based thoracic aortic phenotypes.
Objective: We investigated whether T2DM and glycemic measures (fasting glucose (FG), fasting

49 insulin (FI), glycated hemoglobin (HbA1c), and 2-hour post-load glucose (2hPG)) are causally

50 associated with various imaging and clinical thoracic aortic phenotypes.

51 **Design, setting, and participants**: We performed Mendelian randomization (MR) analysis using 52 summary statistics from genome-wide association studies of glycemic traits (GT) and aortic 53 phenotypes. We employed a two-sample univariate MR (UVMR) followed by a multivariable MR 54 and MR analysis using a cluster-based approach.

55 **Main Outcomes and Measures**: The outcome includes imaging-based ascending and 56 descending aortic diameters (AAoD and DAoD), aortic distensibility (AoDist) and strain (AoStr), 57 and thoracic aortic aneurysm and dissection (TAAD). The GT include FI, FG, HbA1c, 2hPG and 58 T2DM.

59 **Results**: We observed an inverse association between 2hPG, FG, HbA1c, and T2DM and AAoD, 60 DAoD. For instance, the genetically predicted increases levels of 2hPG, FG, HbA1c, and T2DM 61 were associated with decreased AAoD (2hPG β = -0.2, p=3x10⁻⁰⁸; FG β = -0.21, p=5x10⁻⁰⁵; HbA1c β = -0.36, p=2x10⁻⁰⁷; T2DM β =-0.04, p=2x10⁻⁰⁴) and reduce risk TAAD (2hPG decreased TAAD 62 63 (2hPG OR= 0.70, p=4x10⁻⁰⁴; FG OR= 0.58, p=3x10⁻⁰⁵; HbA1c OR= 0.62, p=5x10⁻⁰³; T2DM OR= 64 0.90, p=6x10⁻⁶). Further investigation showed that the inverse association between T2DM and 65 aortic phenotypes is driven by genetic predictors of T2DM beta cell proinsulin clusters. UVMR 66 and Proteomic MR showed a strong association with aortic phenotypes for genes, such as AGER. 67 GLRX, TCF7L2, and GCK, which are known to play an important role in glucose regulation.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 68 **Conclusion and relevance**: Our findings suggest a potentially causal impact of GT on the aortic
- 69 vasculature. Furthermore, specific glucose regulation genes such as GCK, AGER, and TCF7L2
- 70 appear to contribute to this process, opening avenues for potentially leveraging the druggability
- 71 of these genes for treatment or preventions of TAAD.
- 72

It is made available under a CC-BY-NC-ND 4.0 International license .

73 INTRODUCTION

Aortic aneurysm and dissection involve weakening or balloon-like dilation in the aorta's wall, 74 75 often asymptomatic until dissection occurs. These dissections, associated with high mortality 76 rates, result in death in over 90% of cases within 48 hours if untreated¹. The only curative 77 treatment available is surgical; drug-based preventive therapies are lacking, highlighting a huge 78 unmet need for clinical practice. Thoracic aortic aneurysm and dissection (TAAD) is generally 79 linked to genetic disorders of the extracellular matrix and the contractile apparatus but also shares 80 cardiovascular risk factors including male gender, age, smoking, hypertension, and 81 hyperlipidemia². Deep learning has enabled large-scale cardiac phenotyping including aortic measures in biobanks like UK Biobank³. Conducting genome-wide association studies (GWAS) 82 83 on Magnetic Resonance Imaging (MRI)-derived aortic measures has led to the identification of 84 genetic markers linked to aortic morphology and function. These discoveries have enhanced our understanding of the biology and genetics of aortic aneurysms and dissections^{4,5}. Intriguingly, 85 86 epidemiological studies have shown an inverse association between type 2 diabetes (T2DM) and 87 TAAD^{6,7}, however, the causal nature of this relationship remained unknown. A better 88 understanding of the mechanisms underlying the negative association could help the 89 development of innovative diagnostic and therapeutic approaches.

90 Observational studies can be marred with various types of errors such as confounding, 91 reverse causation, mediation bias, or inability to fully differentiate the direct effect of T2DM on 92 aortic aneurysms independent of upstream factors such as obesity and hypertension. Moreover, 93 extant epidemiological studies have seldom examined the full spectrum of GT related to T2DM. 94 such as insulin markers, glycated hemoglobin (HbA1c), fasting blood glucose (FG), and 2hour 95 post glucose load (2hPG), which may offer unique insight into the link between dysglycemia and 96 aortic structure and TAAD. However, very few studies have examined imaging-based subclinical 97 aortic structure, that could indicate earlier stages of the aortic disease process.

It is made available under a CC-BY-NC-ND 4.0 International license .

Mendelian randomization (MR) utilizes genetic variations associated with exposures to assess potentially causal relationships between exposures and outcomes while controlling for confounding factors⁸. We aimed to investigate whether T2DM and various glycemic traits (FG, FI, HbA1c, and 2hPG) affect thoracic aortic structure and subsequently influence the development of TAAD using a comprehensive multi-omic approach. This approach includes an MR analysis across multiple populations, an innovative clustering-based MR analysis, proteomic MR, transcriptome-wide association (TWAS), and gene/pathway enrichment analysis.

105 METHODS

106 **Study population.**

All epidemiological analyses were conducted using data from the UK Biobank (UKBB) under application number 87,255. We analyzed approximately 30,000 participants who had undergone cardiac MRI, from which aortic phenotypes were extracted. To examine the association with TAAD, we utilized the full cohort of UKBB participants (1,135 cases /405,574 controls).

111 For the MR analysis, genetic summary statistics (SumStat) of associations between genetic 112 variants and MRI-derived aortic phenotypes were obtained from approximately 39,000 UKBB 113 participants from the European population (EUR)^{4,9}. We sourced the SumStat for TAAD¹⁰ from 114 the Million Veteran Program (MVP) for EUR (7,050 cases/330,610 controls), African (AFR) (1,266 115 cases/ 88,107 controls), and Hispanic (HIS) (310 cases/ 34,326 controls) populations. The GT 116 exposure SumStats were derived from the population-specific GWAS of BMI adjusted- FG, FI, 117 HbA1c, or 2hPG in EUR, AFR, and HIS¹¹. The GT GWAS were performed in participants with no 118 diabetes diagnosis, no reported use of diabetes-relevant medication(s); and who had an 119 $FG \le 7 \text{ mmol/L}$ (126 mg/dL), $2hPG \le 11.1 \text{ mmol/L}$ (200 mg/dL) or HbA1c $\le 6.5\%$. IVs for T2DM 120 were selected from EUR, HIS, and AFR-specific meta-analysis of T2DM adjusted on BMI^{12,13}. To 121 avoid sample overlap, we assess the association between T2DM and MRI-derived aortic 122 phenotypes using EUR-only Sumstat which did not include the UKBB data. For the association

It is made available under a CC-BY-NC-ND 4.0 International license .

123 between T2DM and TAAD, we employed T2D population specific SumStat for EUR, AFR, and

124 HIS that did not include data from the Million Veteran Program. The GWAS sample size for GWAS

125 for each trait in each population used in our MR is available in Table S1.

126 Association analysis of aortic phenotypes and glycemic traits

127 First, we examined the epidemiological association of GT, including binary T2DM status, with 128 aortic phenotypes including TAAD in the UKBB. We utilized blood glucose levels at enrollment, 129 specifically random glucose (due to the small number of UKBB participants with both fasting 130 glucose and MRI-derived aortic phenotypes) and HbA1c, and defined T2DM using International 131 Classification of Diseases 10 (ICD-10) code, self-reported medical history and self-reported 132 medication usage for diabetes (Table S2). The MRI-derived aortic measures included the 133 diameter of the ascending aorta (AAoD), descending aorta (DAoD), as well as the distensibility of 134 the ascending (AAoDis) and descending (DAoDis) aorta. These parameters were derived using 135 image segmentation of the transversal image of cardiac MRI, sourced from an extensive dataset 136 of over 1M images obtained from ~39,000 UKBB participants^{4,9,14}. Phenotyping of TAAD was 137 defined using ICD-10 codes, OPCS codes, and self-reported medical history (Table S2).

138 The associations between GT and MRI-derived aortic phenotypes were assessed using 139 multivariable linear regression models while the association between GT and TAAD was 140 assessed using multivariable logistic regression. All analyses were adjusted on body surface area 141 (BSA) at imaging, sex acquired from the central registry at recruitment, lipids level and blood 142 pressure (measured at enrollment), and age at the time of imaging or at enrollment. To mitigate 143 potential confounding by indication, adjustments were made for participants taking 144 antihypertensive medication by adding 10 mmHg to diastolic blood pressure and 15 mmHg to systolic blood pressure¹⁵. For participants on lipid-lowering medications, raw LDL values were 145 146 divided by 0.7 to account for medication influence on lipid levels¹⁶. Participants with diabetes 147 medication usage were classified as T2DM cases.

It is made available under a CC-BY-NC-ND 4.0 International license .

148 Mendelian randomization (MR) analyses

149 Selection of instrumental variables (IV).

150 The IV was defined as SNP with minor allelic frequency (MAF) >0.05, independently associated 151 with the exposure at the GWAS significance ($p<5x10^{-08}$ and $R^2<0.001$). However, to overcome 152 power issues due to the small sample size in GWAS among AFR and HIS, we lowered the pvalue threshold for selecting the IV to a suggestive threshold of $p < 1 \times 10^{-05}$. In a second approach, 153 154 we performed an MR using SNPs that were selected as IVs in EUR and that were nominally 155 significant (p<0.05) in non-EUR. Variants selected as instruments from the exposure GWAS 156 SumStat were then matched to the outcome SumStat. Given the lack of data available for aortic 157 measures in non-EUR, we performed the MR of GT and aortic measurements among EUR-only, 158 while the MR between GT and TAAD was performed independently in EUR, AFR, and HIS.

159 Statistical analyses

160 Figure 1 presents the analysis flowchart. For each exposure-outcome pair, the IV was harmonized 161 to ensure consistency of the effect allele between the exposure and the outcome. An IV was 162 excluded if its variance, as explained by the F statistic, was less than 10 (F < 10 indicates a weak 163 IV) if the MAF < 0.05, or if the SNP appeared to be multi-allelic, Additionally, we used MR-Steiger 164 filtering to exclude SNPs indicating possible reverse causation or for which the effect on the 165 outcome is larger than the exposure¹⁷. The inverse-variance weighted (IVW) method was used 166 as the primary analytical approach to assess the relationship between each exposure-outcome 167 pair. The IVW method is considered most powerful because it depends on the validity of all IVs 168 and can robustly detect associations¹⁸. To investigate heterogeneity, we used the Cochran Q 169 method. The MR-Presso global test was conducted to examine the presence of heterogeneous 170 SNPs, identify outliers, and correct for horizontal pleiotropy¹⁹. In sensitivity analyses, we 171 employed MR-Egger, weighted median, and inverse weighted median methods. The MR-Egger 172 intercept test was specifically utilized to detect potential directional pleiotropy, where the MR-

It is made available under a CC-BY-NC-ND 4.0 International license .

Egger intercept can be interpreted as an estimate of the average horizontal pleiotropic effect of
the genetic variants ²⁰.

175 To address the high likelihood of pleiotropy between GT genetic variants (that is, variants affecting 176 multiple GT simultaneously), we conducted a multivariable MR analysis using MVMR in R²¹. This 177 analysis included all evaluated GTs (FG, FI, 2hPG, and HbA1c) and T2DM for each outcome. 178 Additionally, we performed MVMR incorporating all evaluated GTs and T2DM, along with blood 179 pressure (SBP, DBP) and lipid biomarkers (LDL, HDL) to account for potential confounders in the 180 relation between GT and aortic phenotypes. For exposures and outcomes showing significant 181 heterogeneity after pleiotropy assessment, reverse causation testing and outlier correction, we 182 employed a clustering approach with MR-Clust ²². MR-Clust clusters genetic variants based on 183 their causal effect estimates and define clusters assuming distinct causal mechanisms.

184 To explore the potential biological mechanisms relevant to T2DM driving the observed inverse 185 association with aortic phenotypes, we leveraged the T2DM mechanistic clusters defined by Suzuki et al¹³ for MR. These T2DM mechanistic clusters were derived using a combination of 186 187 dimension reduction and hard clustering of T2DM lead SNPs and their significant association with 188 cardiometabolic traits such as FG, HbA1c, BMI, obesity, blood pressure, lipids biomarkers, and fat tissue percentage¹³. The defined clusters include Beta cell +PI (Proinsulin; 91 SNPs), Beta cell 189 190 -PI (89 SNPs), Residual glycemic (389 SNPs), Body fat (273 SNPs), metabolic syndrome (166 191 SNPs), obesity (233 SNPs), lipodystrophy (45 SNPs), liver and lipid metabolism (3 SNPs). For 192 each of these clusters, we performed an MR analysis with MRI-derived aortic phenotypes and 193 TAAD.

194 Evaluation of the MR assumption

Overall, to ensure that robust conclusions are derived, we rigorously tested the three core MR assumptions: relevance, exchangeability, and exclusion restriction. The relevance assumption

197 was validated by assessing the strength of IV by excluding instruments with an F statistic below 198 10 to avoid weak instrument bias. The exchangeability assumption was addressed through 199 multivariable MR analysis²¹ to distinguish genuine gene-disease associations from spurious ones 200 caused by confounding genetic variants²³. Finally, the exclusion restriction assumption was 201 examined using MR-Steiger filtering¹⁷, which helps confirm that the genetic predictors influenced 202 the outcome solely through exposure.

203 Mendelian Randomization of pQTLs and GT as well as aortic phenotypes

204 To investigate the colocalization of protein quantitative trait loci (pQTLs) and GT as well as aortic 205 phenotypes, we employed summary-data-based Mendelian Randomization (SMR) and the 206 heterogeneity in dependent instruments (HEIDI) test²⁴. GWAS of 2,940 plasma proteins were 207 sourced from the genetically inferred EUR in the UK Biobank²⁵. *cis*-pQTLs were defined as SNPs 208 located 1 Mb upstream and downstream of the protein-coding genes, demonstrating an 209 association with plasma protein levels at $P < 3x10^{-05}$. Multi-allelic SNPs were excluded before the 210 SMR analysis. We conducted SMR analysis integrating GWAS with pQTL data from the UKBB 211 with GWAS of GT, T2DM and aortic phenotypes from EUR. The EUR population in the 1000 212 Genomes Project was used as the reference to estimate the linkage disequilibrium between 213 SNPs. The HEIDI test was then applied to differentiate pleiotropic associations from those due to 214 linkage. Associations passing the Bonferroni-corrected significance threshold in SMR analysis 215 and the HEIDI P > 0.05 were considered robust evidence for colocalization between pQTLs and 216 GWAS.

217 Functional annotation of IVs and transcriptome-wide association studies

To explore the biological implications of GT genetic variants, we first annotated each SNP selected as IV using various annotation tools including Phenoscanner²⁶, SNPNexus²⁷, and Haploreg²⁸. These annotations include eQTL expression look-up for each SNP in various tissues (such as aorta, arteries, heart, and fibroblasts), with eQTL data sourced from GTEx and

It is made available under a CC-BY-NC-ND 4.0 International license .

STARNET^{29,30}. A significant eQTL mapping was defined as an SNP with tissue eQTL p-value < 222 1x10⁻⁰⁵. To further extend our eQTL mapping to genes targeted by our IVs, we performed a 223 224 transcription-wide association (TWAS) study on all GT traits GWAS using S-PrediXcan, a 225 summary-statistics-based gene mapping method available in the MetaXcan software package³¹. The summary statistics were harmonized following the best practices on MetaXcan GitHub 226 227 (https://github.com/hakyimlab/MetaXcan). Using a precomputed expression prediction model 228 utilizing the GTEx database, we inferred tissue-specific gene-trait associations³⁰. Tissues tested 229 include coronary artery, aorta, visceral and subcutaneous adipose, atrial appendage, left 230 ventricle, liver, pancreas, whole blood, and EBV-transformed lymphocyte cells. In sensitivity 231 analyses, we used two different families of prediction models, elastic net-based and MASHRbased, a biologically informed model³². For each trait, FDR p-value correction was conducted 232 233 both by tissue and across all tested tissues.

Gene enrichment analysis

Significant genes from S-PrediXcan that were also gene targets by the IVs in our MR, were tested for GO-term overrepresentation using the enrichGO function within the clusterProfiler package³³. The analysis was performed for each ontology (molecular function, biological process, and cellular component) and significant genes from each trait-tissue pair separately. The universe of genes for each enrichment analysis was defined as genes present in the GTEx tissues summary statistic files. The p-values were corrected using the Benjamini-Hochberg method.

241 **RESULTS**

242 Epidemiological association between GT and aortic phenotypes in the UKBB

The characteristics of our study population are described in Table ST2. We observed an inverse association of HbA1c and T2DM with ascending and descending aortic diameters as well as TAAD risk (Table 1). The inverse association with HbA1c was even stronger among participants without diabetes (Table 1, Table ST4).

It is made available under a CC-BY-NC-ND 4.0 International license .

247 MR Glycemic traits and aortic phenotypes

Aorta diameter and thoracic aortic aneurysm

249 In univariate MR analyses using the IVW method, 2hPG, FG, HbA1c, and T2DM were all inversely 250 associated with AAoD and DAoD but no association was observed with FI (Table S5-6, Figure 2). 251 Notably, the associations of 2hPG, FG, HbA1c, and T2DM with AAoD were significant (Table S6, 252 Figure 2), whereas only the associations of 2hPG and FG with DAoD were significant (Figure 2). 253 We also observed a significantly inverse association of 2hPG, FG, HbA1c, and T2DM with TAAD 254 (Table S6, Figure 2). These observed association with TAAD in Europeans were similarly present 255 among AFR and HIS populations (Figure S3, Table ST6). However, only the association with T2DM in HIS reached statistical significance (β : -0.35, p=7x10⁻⁰³) (Table ST6, Figure S3). In 256 257 sensitivity analyses, a consistent inverse association was observed using MR Egger, weighted 258 median, and weighted modal approaches, which aligned with the aforementioned IVW results 259 (table S5-6, Figure S2).

260

261 In multivariable MR analyses, the inverse associations remained significant for 2hPG and AAoD 262 (β: -0.11, p=2x10⁻⁵); HbA1c and AAoD (β: -0.37, p=4x10⁻⁰³); 2hPG and DAoD (β: -0.08, p=5x10⁻¹) ⁰⁴); 2hPG and TAA (β: -0.27 (OR=0.76), p=2.3x10⁻⁰⁵); FG and TAAD (β: -0.26 (OR=, p=3.5x10⁻¹) 263 264 ⁰²); and T2DM and TAAD (β : -0.07, p=2x10⁻⁰²) (Figure 1, Table ST7). It is noteworthy that some 265 exposures had weak strength of the genetic instruments (F-statistics <10, Table ST7) due to a 266 large number of SNPs used as IVs in the T2DM analysis. In a sensitivity analysis using a different 267 summary statistic with smaller number of genetic instruments for T2DM, we observed similar 268 results with most exposures displaying strong genetic instruments (Table ST8).

269 Aortic strain and distensibility

270 In univariate MR analyses using IVW, we observed that 2hPG exhibited an inverse association

with both DAoDis and AAoDis (β = -0.12, p = 7.5 x 10⁻⁵ and β = -0.11, p = 3.1 x 10⁻³, respectively;

It is made available under a CC-BY-NC-ND 4.0 International license .

see Figure 2). FG and T2DM were significantly associated with DAoDis (β = -0.12, p = 4 x 10⁻³ and β = -0.03, p = 5 x 10⁻³ for FG and T2DM, respectively). Regarding aortic strain (AoSt), FI and HbA1c demonstrated a significant association with strain in the ascending aorta (Figure 2). In multivariable MR analyses, the association between 2hPG and DAoDis remained significant, and the associations between AAoSt and either FI or HbA1c also persisted (Figure 2).

277 Heterogeneity and Sensitivity Analysis

Significant variability was detected using the Q statistic for the associations between DAoD and
HbA1c; TAAD and T2DM; and FI with both AAoD and DAoD (Table ST5), despite addressing
reverse causation, excluding weak instruments, correcting for horizontal pleiotropy and removing
outliers. However, consistent directionality of effects was observed across MR IWV, MR Egger,
weighted median, and weighted modal approaches for most exposure-outcome traits (Table ST5,
Figure S2-4).

284 **MR using the clustering approach**

285 Given that the observed heterogeneity suggests a potential contradiction in the effect direction of 286 the SNPs included in each analysis, we reclassified our IVs into more homogenous groups using 287 a cluster analysis approach and conducted MR within each cluster. We identified, for the outcome 288 AAoD, DAoD, and TAAD, and the exposure HbA1c, FG, and FI respectively, two distinct clusters 289 of associations (Table ST9, Figure 3(a)). These clusters included either one with a positive 290 association and another with a negative association, or two unique clusters with negative 291 associations. For instance, the inverse relationship between FG and AAoD showcased two 292 clusters with inverse associations, of which only one cluster, comprising 20 IVs, was significant 293 $(\beta = -0.88, p = 8.02 \times 10^{-20})$, Figure 3(a)) while the inverse association with the second cluster 294 including 48 IV was not significant (Table ST9. Figure 3(a)). The associations between FI and 295 both AAoD and DAoD, which were non-significant in our overall MR analysis, revealed two distinct 296 clusters with significant associations. One cluster displayed a positive association, while the other

showed an inverse association (Figure 3a). This indicates that a subset of insulin-related genetic instruments may contribute to an increase in aortic diameter, while another set may be linked to a decrease in aortic diameter. Similarly, we observed two distinct clusters with significant associations in opposite directions for FG/TAAD and T2DM/TAAD exposure-outcome pairs. This suggests that the impact of FG or T2DM on TAAD may operate through distinct biological pathways, which are either protective or detrimental.

303 MR using T2DM predefined cluster

304 To further explore the biological processes linking T2DM to MRI-derived aortic phenotypes and 305 TAAD, we conducted MR between aortic phenotypes and clusters of SNPs representing various 306 biological processes implicated in T2DM pathophysiology, as recently described by Suzuki et al 307 ¹³. We found that the beta-cell (+) proinsulin cluster (beta-cell +PI) and the beta-cell (-) proinsulin 308 (beta-cell -PI), characterized by variants that reduce insulin secretion and enhance insulin 309 sensitivity, were significantly inversely associated with AAoD, DAoD, and TAAD (Figure 3b, Table 310 ST10). These associations were most pronounced for the beta-cell -PI clusters. Furthermore, the 311 metabolic syndrome cluster (dominated by fasting glucose, fasting Insulin, visceral adipose 312 tissues, and Glutamine fructose-6-phosphate amidotransferase [GFAT] genes) was inversely 313 associated with AAoD, DAoD, and TAAD, while the obesity cluster was significantly associated 314 with larger DAoD (Figure 3b, Table ST10). Additionally, the lipodystrophy cluster, enriched with 315 body fat, lipid levels, and blood pressure, were associated with an increase in AAoD, DAoD, and 316 TAAD (although the association was not significant), while decreasing strain and distensibility of 317 both ascending and descending aorta (Figure 3b and Figure S5).

318 **Proteomic mendelian randomization**

To better understand the link between glycemic traits and aortic phenotype, we also assessed the impact of proteomic biomarkers on aortic structure and diseases. We performed SMR between UKBB 2940 Olink pQTL and aortic phenotypes and identified few pQTL associated with

It is made available under a CC-BY-NC-ND 4.0 International license .

322 aortic phenotypes (Table ST13, Figure 4a and Figure S6). For instance, COL6A3 pQTL was inversely associated with AAoD, DAoD, and TAAD (Figure 4a). FGF5 pQTL was associated with 323 324 AAoD and AAostr, AGER, ECM1, and IGFBP3 were associated with DAoD, DAoStr, and DAdis 325 respectively (Figure 4a). Other pQTL with significant SMR association includes FADD, GLRX, 326 and AOC3 which are all pQTL biomarkers for cardiometabolic profile (Table ST13). To investigate 327 whether pQTLs associated with GT are also associated with aortic phenotype, we performed SMR 328 analysis for FG, 2hPG, FI, and HbA1c. We then checked for overlap between pQTLs showing 329 significant SMR associations with both aortic phenotypes and GT. We identified 12 proteins 330 associated with HbA1c, 4 proteins associated with FG, 3 proteins for FI, and one protein for 2hPG 331 (Table ST13). Among these identified proteins, only ABO which was associated with 2hPG, was 332 also associated with DAoSt (Table ST13). No other proteins with significant association with GT 333 were also associated with aortic phenotypes. When investigating whether SNPs in these pQTL-334 associated genes have IVs in our MR, we found that SNPs in or near ABO and AGER were 335 present in the UVMR.

Functional annotation and enrichment Analysis of Selected Genetic Instruments

337 Functional annotations of SNPs selected as IVs are available in Table S10 and S16. Overall, we 338 observed that several of our IVs are located in regulatory regions such as promoter/enhancer 339 histone marks, proteins bound, or altered transcription factors binding motifs. Several of our IVs 340 were also missense (ex: rs267738 in CESR2, rs120326 in GCKR, and rs1800562 in HFE), 341 nonsynonymous variants or variants located in 5'UTR of genes. We also observed that several 342 IVs have significant eQTL changes in various heart-related tissues including the aorta (Table 343 S13). For instance, SNPs selected as IVs in GCK, TCF7L2, HFE, ABCC8, and AGER, showed 344 significant eQTL in heart and aortic tissues (Table S13). Our TWAS analysis unveiled a significant 345 enrichment (p<1x10⁻⁰⁵) of genes surrounding our IVs for FG, HbA1c, and T2DM across a range 346 of tissues and cells including the aorta, tibial artery, heart, whole blood, and fibroblasts (Table

347 ST13). When specifically examining the TWAS in aortic tissues, we observed a significant 348 association between various GT and changes in gene expression of GCK, CTSS, HFE, KHK, 349 AGER, and TCF7L2 (Figure 4(b) and Table ST14). Moreover, our gene ontology enrichment 350 utilizing gene targets by our IVs and with notable eQTL expression in aortic tissues showcased a 351 significant enrichment in gene ontology pathways such as carbohydrate kinase activity, glucose 352 homeostasis, intracellular glucose homeostasis, and positive regulation of hormone secretion 353 (Table ST15). Genes playing a key role in these pathways include TCF7L2, GCK, HFE, KHK, and 354 AGER.

355 **DISCUSSION**

356 In this study, we comprehensively assessed the relationship between glycemic traits and aortic 357 phenotypes, using an epidemiological approach, followed by a comprehensive MR across 358 multiple populations, and a multi-omics analysis. Genetic predictors associated with high fasting 359 glucose, HbA1c, 2-hour post-load glucose, and T2DM risk were linked to a decrease in aortic size 360 and a reduced risk of TAAD. In particular, the inverse association with T2DM may be driven by 361 genetic variants associated with beta-cell function. Moreover, glucose regulation genes such as 362 GCK and TCF7L2 are potentially involved in biological processes conferring a protective effect 363 on aortic aneurysm.

364 Our study confirmed and expanded the inverse epidemiological associations between glycemic 365 measures and aortic phenotypes observed in prior research. For instance, increased arterial 366 stiffness, reduced aortic elasticity, and lower rates of development, progression, and mortality 367 from aortic aneurysms have been noted individuals with prediabetes or diabetes³⁴⁻³⁶. 368 Furthermore, among men, an inverse relationship has been observed between high fasting 369 glucose levels and infra-aortic diameter on one hand, and the risk of abdominal aortic aneurysm 370 (AAA) progression one the other hand³⁷. Our MR analyses indicated that genetically predicted 371 T2DM risk, higher HbA1c, FG, and 2hPG levels are associated with smaller AAoD, DAoD, and

It is made available under a CC-BY-NC-ND 4.0 International license .

372 lower risk of TAAD; consistent with previously reported MR studies that examined the impact of 373 GT on TAAD and MRI-derived aortic structure^{38,39}. We also showed, for the first time, an inverse 374 association between GT and TAAD among African and Hispanic populations. However, the 375 association was only significant for T2DM in a Hispanic subgroup, probably due to a lack of power 376 driven by insufficient sample size in ancestry-specific summary statistics.

377 An innovative aspect of our analysis is the application of MR on clusters of genetic variants, which 378 allowed testing the hypothesis of the co-existence of different directional effects within our GT 379 instruments, attributable to distinct biological and molecular pathways. Our approach revealed 380 that certain IVs associated with FG. FI. and HbA1c may correlate with an increase in aortic 381 diameter and TAAD risk. Conversely, other IVs associated with these GTs, were associated with 382 a decreased in a rtic diameter and TAAD risk. For instance, within the cluster of genetic variants 383 showing an inverse association for FG and HbA1c, we identified variants in genes such as GCK 384 and TCF7L2. Indeed, prior studies have suggested that variants in TCF7L2 and GCK are linked to a decreased risk of aortic aneurysm or macrovascular disease^{10,40,41}. On the other hand, among 385 386 variants in the FI cluster associated with a larger aorta diameter or higher risk of TAAD, we noted 387 the variant rs284585 in VEGF, a vascular endothelial growth factor. VEGF is a well-known protein that causes vascular endothelial cells to proliferate, migrate, and become more permeable⁴². 388 389 Moreover, findings suggest that insulin's action may enhance angiogenesis through VEGF and 390 promote vasodilation⁴³ thus possibly increasing the risk of TAAD.

We also utilized the cardiometabolic clusters defined by Suzuki et al ¹³ to investigate the relationship between various aspects of the T2DM metabolic profile and aortic phenotypes. We showed that clusters associated with beta-cell dysfunction—specifically those with a positive association with proinsulin (beta cell (+) PI) and a negative association with proinsulin (beta cell (-) PI)—were inversely correlated with aorta diameter and TAAD. Notably, the beta cell (-) PI cluster exhibited even stronger associations. Of note, the beta cell cluster was dominated by

It is made available under a CC-BY-NC-ND 4.0 International license .

397 genes/loci increasing FG, 2hPG, and HbA1c suggesting that factors affecting glucose
 398 homeostasis have a greater impact on aortic structure and function.

399 We enhanced our MR analysis by additionally conducting a proteomic MR approach, which offers 400 additional insights into proteins involved, and thus potential mechanisms linking GT to aortic 401 structure and disease. This approach helped shed light on the biological pathways contributing to 402 observed genetic associations, thereby strengthening our findings and providing a 403 comprehensive perspective on the molecular underpinnings of aortic phenotypes. Our SMR 404 analysis identified several proteomic biomarkers associated with aortic phenotypes. Notably, 405 COL6A3 pQTL is associated with AAoD. DAoD, and TAAD while AGER pQTL is associated with 406 DAoD. AGER or RAGE is a receptor that binds to advanced glycation end products (AGEs) for 407 degradation. Chronic hyperglycemia leads to the formation of AGEs, which stabilize collagen 408 networks, increase resistance to protease degradation, and reduce aortic wall stress^{7,43–45}. In AAA 409 tissues from individuals with diabetes, increased cross-linking AGEs like pentosidine correlate 410 with smaller AAA diameters, indicating a protective role due to collagen network stabilization^{7,46}. 411 COL6A3 is a core component of collagen type VI, which assembles into microfibrils, forming a 412 scaffold within the extracellular matrix, thus supporting the aortic tissue structure by providing 413 tensile strength and resilience against mechanical stress. COL6A3 can undergo glycation in the 414 setting of hyperglycemia. AGE-modified COL6A3 in the aortic wall could contribute to increased 415 vascular stiffness, influencing blood flow dynamics and vessel function^{47–49}. Further studies are 416 needed to better understand the relation between these protein biomarkers and aortic phenotype 417 in hyperglycemic conditions.

Functional annotation of IVs revealed an enrichment of functional impact for multiple SNPs. this includes the presence of missense variants among our IVs, SNPs located in regulatory elements such as transcription factor binding sites, enhancers, and promotors active in aortic tissues. This includes SNPs in genes such as *GCK* that also show significant enrichment in aortic tissues from

It is made available under a CC-BY-NC-ND 4.0 International license .

422 our TWAS. GCK, a glucokinase linked to maturity-onset diabetes of the young (MODY2), a rare 423 monogenic diabetes where elevated blood glucose levels remain stable without worsening 424 glycemic control^{41,50}. Studies have suggested that patients with GCK- MODY2 exhibit a lower risk 425 of diabetes-related micro- and macro-vascular complications⁴¹. Glucokinase activation, targeting 426 GCK, has recently emerged as a potential diabetes therapy, which is either FDA approved (tofogliflozin) or tested in phase II or III clinical trials (ex: GKA-50 and dorzagliatin)⁵¹⁻⁵⁴. In our 427 428 study, SNPs in GCK were included as IVs for the HbA1c, FG, and the T2DM beta cell (-) PI cluster. 429 Molecules targeting GCK in diabetes treatment could be good candidates for repurposing to 430 TAAD treatment and prevention given the impact of GCK on decreasing the aorta diameter.

431 Another interesting finding provided by MR, functional annotation and TWAS analysis in aortic 432 tissue is the evidence to support the causal effect of *TCF7L2* gene on adverse aortic phenotypes. 433 An inverse association between TCF7L2 locus and TAA was previously described by Roychowshury et al⁴⁰. However, in the latter study, the inverse association observed at the locus 434 435 was driven by a set of variants also independently associated with an increased risk of diabetes. 436 They suggested that the inverse association between T2DM and TAAD at this locus reflects independent gene-level horizontal pleiotropy⁴⁰. In our TWAS, *TCF7L2* gene expression in aortic 437 438 tissues was inversely associated with HbA1c, FG, 2hPG, and T2DM. Furthermore, SNPs in 439 TCF7L2 including rs7903146 were IVs for 2hGP, HbA1c (-) association cluster, FG (-) association 440 cluster as well as in the T2D beta cell (+) PI cluster. Indeed, rs7903146 is a known diabetes 441 candidate SNP⁵⁵. In our analysis, rs7903146 showed an inverse association with 2hPG, FG, 442 HbA1c, and T2DM with the directionality of the effect consistent with the association of TCF7L2 variants rs4077257 reported by Roychowshury et al⁴⁰. A genetic correlation analysis conducted 443 444 on a European population revealed a correlation coefficient (R²) of 0.46 between the genetic 445 variants rs7903146 and rs4077257. Based on these findings, we hypothesize that the observed 446 inverse association between the TCF7L2 gene and aortic phenotypes may be mediated through

It is made available under a CC-BY-NC-ND 4.0 International license .

glucose levels, independent of diabetes status. Further research is warranted to investigate thishypothesis in greater detail.

449 Our pathway analyses identified several pathways with high enrichment of genes targeted by the 450 IVs in our MR study. These pathways include carbohydrate kinase activity, glucose homeostasis. 451 response to intracellular glucose homeostasis, response to monosaccharides, regulation of the 452 glycolytic process, peptide secretion, and response to carbohydrates. Key genes involved are 453 GCK, TCF7L2, KHK, HFE, and AGER. These interconnected pathways are crucial for maintaining 454 glucose balance and cellular energy management. For example, carbohydrate kinase activity and 455 alucose homeostasis regulate glucose levels and limit AGE formation. As mentioned above. 456 accumulation of AGEs affects the extracellular matrix remodeling of the aortic wall by cross-linking 457 with ECM proteins such as collagen and elastin which could increase aortic wall stiffness⁷. Thus, 458 possibly contributing to the observed decreased risk of aortic aneurysm in diabetes and 459 hyperglycemia.

460 **Strengths and limitations**

461 To our knowledge, our study is the first to investigate the role of GT on TAAD among non-462 European populations. Furthermore, this is the first comprehensive study to assess the 463 relationship between GT/diabetes and aortic phenotypes using a multi-omic approach that 464 includes MR, clustering MR analysis, proteomic MR, TWAS, and gene/pathway enrichment 465 analysis. The validity and robustness of our findings are supported using a two-sample MR 466 technique with the latest GWAS summary statistics data available for exposure-outcome traits, 467 supplemented by MR cluster analysis. A limitation of our study is that we could not assess the 468 causal relationship between glycemic traits and aortic structure in non-European populations. 469 However, our results showing an inverse association between glycemic traits and thoracic aortic 470 aneurysm suggest that the direction of these associations is consistent across different 471 ancestries.

It is made available under a CC-BY-NC-ND 4.0 International license .

472 CONCLUSION

- 473 Genetic predictors associated with high fasting glucose, HbA1c, 2-hour post-load glucose, and
- 474 T2DM risk are causally linked to a decrease in aortic size and a reduced risk of TAAD. The inverse
- 475 association with T2DM may be driven by genetic variants associated with beta-cell function. The
- 476 study highlights the potential involvement of glucose regulation genes such as GCK and TCF7L2.
- 477 Hence, drug targeting GCK such as glucokinase activators, or interacting with TCF7L2 such as
- 478 metformin, could be potential good candidate to be repurposed for treating and preventing TAAD.
- 479 Future preclinical/clinical research is needed to better understand this opportunity.

480

It is made available under a CC-BY-NC-ND 4.0 International license .

481 References

- Elefteriades JA, Sang A, Kuzmik G, Hornick M. Guilt by association: paradigm for
 detecting a silent killer (thoracic aortic aneurysm). *Open Heart*. 2015;2(1):e000169.
 doi:10.1136/openhrt-2014-000169
- 485
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
- 487 3. Petersen SE, Matthews PM, Francis JM, et al. UK Biobank's cardiovascular magnetic
 488 resonance protocol. *J Cardiovasc Magn Reson*. 2016;18:8. doi:10.1186/s12968-016-0227489 4
- 490 4. Pirruccello JP, Chaffin MD, Chou EL, et al. Deep learning enables genetic analysis of the 491 human thoracic aorta. *Nat Genet*. 2022;54(1):40-51. doi:10.1038/s41588-021-00962-4
- 492 5. Benjamins JW, Yeung MW, Van De Vegte YJ, et al. Genomic insights in ascending aortic
 493 size and distensibility. Published online 2022. doi:10.1016/j
- 494 6. D'cruz RT, Wee IJY, Syn NL, Choong AMTL. The association between diabetes and
 495 thoracic aortic aneurysms. *J Vasc Surg.* 2019;69(1):263-268.e1.
 496 doi:10.1016/j.jvs.2018.07.031
- 497 7. Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z. Diabetes and
 498 aortic aneurysm: current state of the art. *Cardiovasc Res.* 2018;114(13):1702-1713.
 499 doi:10.1093/cvr/cvy174
- Minelli C, Del Greco M F, van der Plaat DA, Bowden J, Sheehan NA, Thompson J. The
 use of two-sample methods for Mendelian randomization analyses on single large
 datasets. *Int J Epidemiol*. 2021;50(5):1651-1659. doi:10.1093/ije/dyab084
- 503 9. Tcheandjieu C, Xiao K, Tejeda H, et al. High heritability of ascending aortic diameter and
 504 trans-ancestry prediction of thoracic aortic disease. *Nat Genet*. 2022;54(6):772-782.
 505 doi:10.1038/s41588-022-01070-7
- 506 10. Klarin D, Devineni P, Sendamarai AK, et al. Genome-wide association study of thoracic
 507 aortic aneurysm and dissection in the Million Veteran Program. *Nat Genet*.
 508 2023;55(7):1106-1115. doi:10.1038/s41588-023-01420-z
- 50911.Chen J, Spracklen CN, Marenne G, et al. The trans-ancestral genomic architecture of510glycemic traits. Nat Genet. 2021;53(6):840-860. doi:10.1038/s41588-021-00852-9
- 511 12. Mahajan A, Spracklen CN, Zhang W, et al. Multi-ancestry genetic study of type 2 diabetes
 512 highlights the power of diverse populations for discovery and translation. *Nat Genet*.
 513 2022;54(5):560-572. doi:10.1038/s41588-022-01058-3
- 514 13. Suzuki K, Hatzikotoulas K, Southam L, et al. Genetic drivers of heterogeneity in type 2
 515 diabetes pathophysiology. *Nature*. 2024;627(8003):347-357. doi:10.1038/s41586-024516 07019-6
- 517 14. Pirruccello JP, Rämö JT, Choi SH, et al. The Genetic Determinants of Aortic Distention. J
 518 Am Coll Cardiol. 2023;81(14):1320-1335. doi:10.1016/j.jacc.2023.01.044
- 519 15. Surendran P, Feofanova E V., Lahrouchi N, et al. Discovery of rare variants associated
 520 with blood pressure regulation through meta-analysis of 1.3 million individuals. *Nat*521 *Genet*. 2020;52(12):1314-1332. doi:10.1038/s41588-020-00713-x
- 522 16. Graham SE, Clarke SL, Wu KHH, et al. The power of genetic diversity in genome-wide
 523 association studies of lipids. *Nature*. 2021;600(7890):675-679. doi:10.1038/s41586-021524 04064-3

525 526 527	17.	Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. <i>PLoS Genet</i> . 2017;13(11):e1007081_doi:10.1371/journal.pgen.1007081
528 529 530	18.	Nikolakopoulou A, Mavridis D, Salanti G. How to interpret meta-analysis models: fixed effect and random effects meta-analyses. <i>Evid Based Ment Health</i> . 2014;17(2):64.
531 532	19.	Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diaganage. <i>Net Causet</i> 2018;50(5):602-608, doi:10.1028/a41588-018-0000-7
535 534 535	20.	Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. <i>Eur J Epidemiol.</i> 2017;32(5):377-389. doi:10.1007/s10654-017-0255-
536		X
537	21.	Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable
538 539		Mendelian randomization in the single-sample and two-sample summary data settings. <i>Int J Epidemiol</i> . 2019;48(3):713-727. doi:10.1093/ije/dyy262
540	22.	Foley CN, Mason AM, Kirk PDW, Burgess S. MR-Clust: Clustering of genetic variants in
541 542		Mendelian randomization with similar causal estimates. <i>Bioinformatics</i> . 2021;37(4):531-541. doi:10.1093/bioinformatics/btaa778
543	23.	Zheng J. Haberland V. Baird D. et al. Phenome-wide Mendelian randomization mapping
544		the influence of the plasma proteome on complex diseases. <i>Nat Genet</i> . 2020;52(10):1122-
545		1131. doi:10.1038/s41588-020-0682-6
546	24.	Sun BB, Chiou J, Traylor M, et al. Plasma proteomic associations with genetics and health
547		in the UK Biobank. <i>Nature</i> . 2023;622(7982):329-338. doi:10.1038/s41586-023-06592-6
548	25.	Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL studies
549		predicts complex trait gene targets. Nat Genet. 2016;48(5):481-487. doi:10.1038/ng.3538
550	26.	Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for
551		searching human genotype-phenotype associations. <i>Bioinformatics</i> . 2019;35(22):4851-
552		4853. doi:10.1093/bioinformatics/btz469
553	27.	Oscanoa J, Sivapalan L, Gadaleta E, Dayem Ullah AZ, Lemoine NR, Chelala C.
554		SNPnexus: a web server for functional annotation of human genome sequence variation
555		(2020 update). Nucleic Acids Res. 2020;48(W1):W185-W192. doi:10.1093/nar/gkaa420
556	28.	Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell
557		types, regulators and target genes for human complex traits and disease. Nucleic Acids
558		<i>Res</i> . 2016;44(D1):D877-81. doi:10.1093/nar/gkv1340
559	29.	Jupiter D, Chen H, VanBuren V. STARNET 2: a web-based tool for accelerating
560		discovery of gene regulatory networks using microarray co-expression data. BMC
561		Bioinformatics. 2009;10:332. doi:10.1186/1471-2105-10-332
562	30.	Wheeler HE, Shah KP, Brenner J, et al. Survey of the Heritability and Sparse Architecture
563		of Gene Expression Traits across Human Tissues. <i>PLoS Genet</i> . 2016;12(11):e1006423.
564		doi:10.1371/journal.pgen.1006423
565	31.	Barbeira AN, Dickinson SP, Bonazzola R, et al. Exploring the phenotypic consequences
366		of tissue specific gene expression variation inferred from GWAS summary statistics. <i>Nat</i>
567	22	<i>Commun.</i> 2018;9(1):1825. doi:10.1038/s41467-018-03621-1
568	32.	Araujo DS, Nguyen C, Hu X, et al. Multivariate adaptive shrinkage improves cross-
569		population transcriptome prediction for transcriptome-wide association studies in

570		underrepresented populations. <i>bioRxiv</i> . Published online May 20, 2023.
571		doi:10.1101/2023.02.09.527747
572	33.	Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting
573		omics data. Innovation (Cambridge (Mass)). 2021;2(3):100141.
574		doi:10.1016/j.xinn.2021.100141
575	34.	Aslan AN, Ayhan H, Çiçek ÖF, et al. Relationship between aortic stiffness and the left
576		ventricular function in patients with prediabetes. Intern Med. 2014;53(14):1477-1484.
577		doi:10.2169/internalmedicine.53.1720
578	35.	Dec-Gilowska M, Trojnar M, Makaruk B, Mosiewicz-Madejska B, Dzida G, Mosiewicz J.
579		Local elasticity of the aorta in patients with type 2 diabetes mellitus. J Int Med Res.
580		2020;48(9):300060520952643. doi:10.1177/0300060520952643
581	36.	Prakash SK, Pedroza C, Khalil YA, Milewicz DM. Diabetes and reduced risk for thoracic
582		aortic aneurysms and dissections: a nationwide case-control study. J Am Heart Assoc.
583		2012:1(2). doi:10.1161/JAHA.111.000323
584	37.	Le MTO, Jamrozik K, Davis TME, Norman PE, Negative Association between Infra-renal
585		Aortic Diameter and Glycaemia: The Health In Men Study. <i>European Journal of Vascular</i>
586		and Endovascular Surgery, 2007:33(5):599-604. doi:10.1016/j.eivs.2006.12.017
587	38.	Zhang Y. Li Y. Dai X. Lin H. Ma L. Type 2 diabetes has a protective causal association
588	201	with thoracic aortic aneurysm: a Mendelian randomization study. <i>Diabetol Metab Syndr</i> .
589		2023:15(1) doi:10.1186/s13098-023-01101-1
590	39.	Li Z. Xiong J. Guo Y. et al. Effects of diabetes mellitus and glycemic traits on
591	071	cardiovascular morpho-functional phenotypes. <i>Cardiovasc Diabetol</i> , 2023;22(1):336
592		doi:10.1186/s12933-023-02079-w
593	40.	Roychowdhury T. Lu H. Hornsby WE. et al. Regulatory variants in TCF7L2 are
594		associated with thoracic aortic aneurysm Am I Hum Genet 2021:108(9):1578-1589
595		doi:10.1016/j.aibg.2021.06.016
596	41	Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT, Prevalence
597		of vascular complications among patients with glucokinase mutations and prolonged mild
598		hyperglycemia. JAMA. 2014:311(3):279-286. doi:10.1001/jama.2013.283980
599	42	Aiello LP Wong IS Role of vascular endothelial growth factor in diabetic vascular
600	12.	complications <i>Kidney Int Suppl</i> 2000:77:S113-9 doi:10.1046/j.1523-1755.2000.07718 x
601	43	Fu I Yu MG Li O Park K King GL Insulin's actions on vascular tissues: Physiological
602	15.	effects and nathonhysiological contributions to vascular complications of diabetes <i>Mol</i>
603		<i>Metab</i> 2021:52:101236 doi:10.1016/i molmet 2021.101236
604	44	Zieman SI Kass DA Advanced Glycation End Product Cross-Linking: Pathonhysiologic
605		Role and Therapeutic Target in Cardiovascular Disease. <i>Congestive Heart Failure</i>
606		2004·10(3)·144-151_doi:10.1111/i 1527-5299.2004.03223 x
607	45	Golledge I Karan M Moran CS et al Reduced expansion rate of abdominal aortic
608	15.	aneurysms in patients with diabetes may be related to aberrant monocyte-matrix
609		interactions Fur Heart I 2008:29(5):665-672 doi:10.1093/eurbearti/ehm557
610	46	Golledge I Karan M Moran CS et al Reduced expansion rate of abdominal aortic
611	- 0.	aneurysms in patients with diabetes may be related to aberrant monocyte-matrix
612		interactions Fur Heart I 2008.29(5).665_672 doi:10.1003/eurhearti/ehm557
613	<i>4</i> 7	Singh SN Vats P Suri S et al Effect of an antidiabetic extract of Catharanthus researce on
614	Τ /.	enzymic activities in streptozotocin induced diabetic rats. <i>I Ethnonharmacol</i>
615		2001.76(3).260.277 doi:10.1016/S0378.87/1/01)0025/ 0
015		2001,10(3).207-211. 001.10.1010/30310-0141(01)00234-7

- 48. Bosco C, Alegana V, Bird T, et al. Exploring the high-resolution mapping of genderdisaggregated development indicators. *J R Soc Interface*. 2017;14(129):20160825.
 doi:10.1098/rsif.2016.0825
- 619 49. Sakai M, Troutman TD, Seidman JS, et al. Liver-Derived Signals Sequentially Reprogram
 620 Myeloid Enhancers to Initiate and Maintain Kupffer Cell Identity. *Immunity*.
 621 2019;51(4):655-670.e8. doi:10.1016/j.immuni.2019.09.002
- 50. Fendler W, Rizzo M, Borowiec M, et al. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. *Acta Diabetol*.
 2014;51(4):625-632. doi:10.1007/s00592-014-0567-1
- 625 51. Ren Y, Li L, Wan L, Huang Y, Cao S. Glucokinase as an emerging anti-diabetes target
 626 and recent progress in the development of its agonists. *J Enzyme Inhib Med Chem*.
 627 2022;37(1):606-615. doi:10.1080/14756366.2021.2025362
- 52. Ikeda S, Takano Y, Cynshi O, et al. A novel and selective sodium-glucose cotransporter-2
 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients
 with type 2 diabetes mellitus. *Diabetes Obes Metab.* 2015;17(10):984-993.
 doi:10.1111/dom.12538
- 632 53. Ren Y, Li L, Wan L, Huang Y, Cao S. Glucokinase as an emerging anti-diabetes target
 633 and recent progress in the development of its agonists. *J Enzyme Inhib Med Chem*.
 634 2022;37(1):606-615. doi:10.1080/14756366.2021.2025362
- 54. Zhu D, Li X, Ma J, et al. Dorzagliatin in drug-naïve patients with type 2 diabetes: a
 randomized, double-blind, placebo-controlled phase 3 trial. *Nat Med.* 2022;28(5):965-973.
 doi:10.1038/s41591-022-01802-6
- 638 55. Cropano C, Santoro N, Groop L, et al. The rs7903146 Variant in the TCF7L2 Gene
 639 Increases the Risk of Prediabetes/Type 2 Diabetes in Obese Adolescents by Impairing β640 Cell Function and Hepatic Insulin Sensitivity. *Diabetes Care*. 2017;40(8):1082-1089.
 641 doi:10.2337/dc17-0290
- 641 doi:10.233//dc
- 642
- 643

644



Figure 1: Flowchart Mendelian Randomization analysis investigating the causal association between glycemic traits and aortic measurement and diseases. Sample size description for each summary statistic is presented in the table S2.

Exposure	Beta	Ascending	aortic diameter pval	Exposure	Beta	Ascending aortic	c distensibility pval	Beta	Ascending ac	ortic strain pval
2-hour post-load glucose (2hPG)	-0.2 -0.11	()	3.7e-08 1.5e-05	2-hour post-load glucose (2hPG)	-0.11	D	3.1e-03	-0.04	O	0.18
Fasting glucose (FG)	-0.21 5.1e-05 -0.01 0.89		5.1e-05 0.89				0.44	-0.01		0.66
Glycated hemoglobin (HbA1c)	-0.36 -0.37		1.7e-07 1.5e-03	Fasting glucose (FG)	0 0.05		0.92 0.48	0.05 0.03		0.28 0.62
Fasting Insulin (FI)	-0.06 0.19	0	0.59 0 5.1e-03	Glycated hemoglobin (HbA1c)	0.12	O	0.04	0.19		1.2e-03
Type 2 diabetes mellitus (T2DM)	-0.03 0.01		1.7e-03 0.45		0.09		0.45	0.06		0.61
Exposure	;	Descending	aortic diameter	Fasting Insulin (FI)	-0.18	0	0.02	-0.19	0	0.03
2-hour post-load glucose (2hPG)	-0.11		1.2e-05		-0.17		0.01	-0.19	0	3.1e-03
	-0.08		4.9e–04		-0.03	Ē	5.0e-03	0	•	0.85
Fasting glucose (FG)	-0.16 O		9.7e-05 0.53	Type 2 diabetes mellitus (T2DM)	-0.03	ē	0.04	0	Ţ	0.88
Churched homoglobin (HbA1a)	-0.1 0.1 -0.12 0.23		0.1	-	Descending aortic distensibility			Descending aortic strain		
Giycated hemoglobin (HDATC)	-0.12		0.23	Exposure		Descending aorti			Descending a	
Fasting Insulin (FI)	-0.12 -0.02 0.16		0.23 0.86 6.8e-03	Exposure 2-hour post-load glucose (2hPG)	-0.12		7.6e-05	-0.07		0.04
Fasting Insulin (FI) Type 2 diabetes mellitus (T2DM)	-0.12 -0.02 0.16 0 0.03		0.23 0.86 6.8e-03 0.62 0.02	Exposure 2-hour post-load glucose (2hPG)	-0.12 -0.05		7.6e–05 0.04	-0.07 -0.04		0.04 0.12
Fasting Insulin (FI) Type 2 diabetes mellitus (T2DM)	-0.12 -0.02 0.16 0 0.03		0.23 0.86 6.8e-03 0.62 0.02	Exposure 2-hour post-load glucose (2hPG) Fasting glucose (FG)	-0.12 -0.05 -0.12		7.6e-05 0.04 4.2e-03	-0.07 -0.04 0.02	O O O	0.04 0.12 0.64
Fasting Insulin (FI) Type 2 diabetes mellitus (T2DM) Exposure	-0.12 -0.02 0.16 0 0.03	Thoratic a	0.23 0.86 6.8e-03 0.62 0.02 ortic aneurysm	2-hour post-load glucose (2hPG) Fasting glucose (FG)	-0.12 -0.05 -0.12 0.01		7.6e-05 0.04 4.2e-03 0.89	-0.07 -0.04 0.02 -0.05		0.04 0.12 0.64 0.4
Fasting Insulin (FI) Type 2 diabetes mellitus (T2DM) Exposure 2-hour post-load glucose (2hPG)	-0.12 -0.02 0.16 0 0.03 -0.35 -0.26	Thoratic a	0.23 0.86 6.8e-03 0.62 0.02 0.02 0.02 0.02	Exposure 2-hour post-load glucose (2hPG) Fasting glucose (FG)	-0.12 -0.05 -0.12 0.01 -0.13		7.6e-05 0.04 4.2e-03 0.89 0.05	-0.07 -0.04 0.02 -0.05 -0.12		0.04 0.12 0.64 0.4 0.06
Give a led hemoglobilit (HDA1C) Fasting Insulin (FI) Type 2 diabetes mellitus (T2DM) Exposure 2-hour post-load glucose (2hPG) Fasting glucose (FG)	-0.12 -0.02 0.16 0 0.03 -0.35 -0.26 -0.54 -0.31		0.23 0.86 6.8e-03 0.62 0.02 0.02 0.02 0rtic aneurysm 3.8e-04 2.2e-04 2.8e-05 0.03	Exposure 2-hour post-load glucose (2hPG) Fasting glucose (FG) Glycated hemoglobin (HbA1c)	-0.12 -0.05 -0.12 0.01 -0.13 -0.17		7.6e-05 0.04 4.2e-03 0.89 0.05 0.11	-0.07 -0.04 0.02 -0.05 -0.12 -0.22		0.04 0.12 0.64 0.4 0.06 0.05
Glycated hemoglobin (HbA1C) Fasting Insulin (FI) Type 2 diabetes mellitus (T2DM) Exposure 2-hour post-load glucose (2hPG) Fasting glucose (FG) Glycated hemoglobin (HbA1c)	-0.12 -0.02 0.16 0 0.03 -0.35 -0.26 -0.54 -0.54 -0.31 -0.48 -0.03		0.23 0.86 6.8e-03 0.62 0.02 0.02 0.02 0rtic aneurysm 3.8e-04 2.2e-04 2.8e-05 0.03 5.2e-03 0.89	Exposure 2-hour post-load glucose (2hPG) Fasting glucose (FG) Glycated hemoglobin (HbA1c) Fasting Insulin (FI)	-0.12 -0.05 -0.12 0.01 -0.13 -0.17 -0.15		7.6e-05 0.04 4.2e-03 0.89 0.05 0.11 0.07	-0.07 -0.04 0.02 -0.05 -0.12 -0.22 -0.19		0.04 0.12 0.64 0.4 0.06 0.05 0.06
Glycated hemoglobin (HbA1C) Fasting Insulin (FI) Type 2 diabetes mellitus (T2DM) Exposure 2-hour post-load glucose (2hPG) Fasting glucose (FG) Glycated hemoglobin (HbA1c)	-0.12 -0.02 0.16 0 0.03 -0.35 -0.26 -0.54 -0.31 -0.48 -0.03 -0.2		0.23 0.86 6.8e-03 0.62 0.02 0.02 0.02 0.02 0.02 0.02 0.03 5.2e-04 2.8e-05 0.03 5.2e-03 0.89 0.43	Exposure 2-hour post-load glucose (2hPG) Fasting glucose (FG) Glycated hemoglobin (HbA1c) Fasting Insulin (FI)	-0.12 -0.05 -0.12 0.01 -0.13 -0.17 -0.15 -0.13		7.6e-05 0.04 4.2e-03 0.89 0.05 0.11 0.07 0.05	-0.07 -0.04 0.02 -0.05 -0.12 -0.22 -0.19 -0.15		0.04 0.12 0.64 0.4 0.06 0.05 0.06 0.02
Glycated hemoglobin (HbA1C) Fasting Insulin (FI) Type 2 diabetes mellitus (T2DM) Exposure 2-hour post-load glucose (2hPG) Fasting glucose (FG) Glycated hemoglobin (HbA1c) Fasting Insulin (FI)	-0.12 -0.02 0.16 0 0.03 -0.35 -0.26 -0.54 -0.31 -0.48 -0.03 -0.2 0.44		0.23 0.86 6.8e-03 0.62 0.02 0.02 0.02 0.02 0.02 0.02 0.03 5.2e-04 2.8e-05 0.03 5.2e-03 0.89 0.43 0.02	2-hour post-load glucose (2hPG) Fasting glucose (FG) Glycated hemoglobin (HbA1c) Fasting Insulin (FI)	-0.12 -0.05 -0.12 0.01 -0.13 -0.13 -0.15 -0.13 -0.13		7.6e-05 0.04 4.2e-03 0.89 0.05 0.11 0.07 0.05 1.4e-06	-0.07 -0.04 0.02 -0.05 -0.12 -0.22 -0.19 -0.15 -0.02		0.04 0.12 0.64 0.4 0.06 0.05 0.06 0.02 0.05
Glycated hemoglobin (HbA1c) Fasting Insulin (FI) Type 2 diabetes mellitus (T2DM) Exposure 2-hour post-load glucose (2hPG) Fasting glucose (FG) Glycated hemoglobin (HbA1c) Fasting Insulin (FI) Type 2 diabetes mellitus (T2DM)	-0.12 -0.02 0.16 0 0.03 -0.35 -0.26 -0.54 -0.31 -0.48 -0.03 -0.2 0.44 -0.11 -0.08		0.23 0.86 6.8e-03 0.62 0.02 0.02 0rtic aneurysm 3.8e-04 2.2e-04 2.8e-05 0.03 5.2e-03 0.89 0.43 0.02 6.2e-06 0.04	Exposure 2-hour post-load glucose (2hPG) Fasting glucose (FG) Glycated hemoglobin (HbA1c) Fasting Insulin (FI) Type 2 diabetes mellitus (T2DM)	-0.12 -0.05 -0.12 0.01 -0.13 -0.13 -0.15 -0.13 -0.05 -0.02		7.6e-05 0.04 4.2e-03 0.89 0.05 0.11 0.07 0.05 1.4e-06 0.17	-0.07 -0.04 0.02 -0.05 -0.12 -0.22 -0.19 -0.15 -0.02 0.02		0.04 0.12 0.64 0.4 0.06 0.05 0.05 0.02 0.05 0.22

	Glycated hemo	globin (HbA1C)			Fasting	g glucose	(FG)	Fasting Insulin				
n.SNPs	Ascending aorta diameter pvalue			n.SNPs Ascending aorta diameter pvalue				pvalue	n.SNPs	a diameter	pvalue		
20				8.5e-03	20				8.9e-20	29	-		0.13
51				1.2e-18	48		-		0.08	6	•		1.1e-08
71		-		1.7e-07	68	-			5.1e-05	35			0.59
	Descending	aorta diamet	er			Desce	nding aorta dian	neter			Descending aort	a diameter	
62				0.03	8				0.03	15	-		1.4e-09
10		 =		2.1e-05	57				1.6e-10	21		_	2.2e-05
72		-	+	0.1	65	+			9.7e-05	36			0.86
	Thoracic aor	tic aneurysm	ı			Thorac	ic aortic aneury	/sm	Thoracic aortic aneurysm				
62			╡──	0.84	4				7.8e03				
12				4.1e-09	66				1.9e-07	34			0.43
74				5.2e-03	70				2.8e-05				
-3	-2 - Effect estimate	1 per unit chan	0 ge	1	-2	-1 Effect es	0 1 stimate per unit ch	l 2 nange	!		-1 Effect estimate per	0 unit change	1

B)

* T2D * Body Fat * Lipid & Liver Metabolism * Residual Glycemia * Beta cell plus PI
 * Obesity * Lipodystrophy * Metabolic Syndrome * Beta cell minus PI

Cluster	Example Insulin genes/loci Secretion		Insulin Sensitivitv		Ascending	j aorta dian	neter			Descending ac	rta diameter			Thoracic aortic	aneurysm	
Beta cells (+) pro-Insulin	TCF7L2 , KCNQ1, SLC30A8	_	+	38 ₂₉	-	-0.09	0.32	1.7e-02	50	-	-0.04 0.08	₂₇ 0.02	34	 0.04	0.2	5.2e–06
Beta cells (-) pro-Insulin	CDC123, GCK, HKI CAMK1D, ABCC8	H, 8 -	+	32 ₃₄	+	-0.0	3 2.5e–08	0.35 ₃₇	48	-	-0.09 -0.02	₂₈ 2.5e–04	-34	-0. 1.3e-05	22	6.3e–03
Residual glycemia	GCC1-PAX4-LEP, ANKRD55, GCKR	-	-	107 ₇₁	-		0.94	0.98 ₆₈	157		0.02 0.53	₅₇ 0.22	70	- 0.81	-0.09	0.18
Metabolic syndrome	IFG2BP2, CCND2, JAZF1	+	-	62 ₄₃		-0.07	3.2e-04	4.9e-Q4	88	-	-0.07 10 .08	₄₂ 7.9e–04	_48	-0.3 7.9e-03	-	6.4e-07
Liver_lipid metabolism	TOMM40-POE, TM6SF2, PNPLA3	+	-	22			0.61	0.61 ₂	2		0.08	∎ 2 0.41	2	-0.71	-	0.01
Lipodystrophy	IRS1, GRB14-COBBI PPARG	-1, +	-	26 ₂₃	-		0.73	0.73 ₂₀	32		0.04 0.26	₂₅ 0.16	25	0.45	0.11	0.18
Body fat	ZMIZ1, HMGA2, CTE	3P1 +	-	84 ₄₉		-0.0	0.13	0.06 ₅₅	135		-0.04 0.04	₃₆ 0.1	47	- 0.88	0.17	0.06
Obesity	FTO, MC4R, MACF TMeM18	1, _	-	80 ₅₅	_	- 0	0.86	0.53 ₇₀	125	-=-	0.15 8.6e-05 🛨	₅₉ 2.7e–15	78	- 0.8		0.97
Type 2 diabetes (main results)	-			241 ₁₈₅	-	-0.0	5.5e-08	3.9e-0275	350	•	0 0. <mark>3</mark> 7	₁₆₉ 0.73	220-	-0 1.0e-05	.19	3.3e–09
			-	-1.5 –	1.0 –0.	5 0.	0 0).5 –1	.5	-1.0 -0.5 Effect estimate p	0.0 er unit change	0.5 –	1.5 –	1.0 –0.5	0.0	0.5

A)

